Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eltrombopag for Poor Graft Function After Allo-HCT
NCT03948529Phase 2Terminated
- Sponsor
- CHU de Lille
- Start
- Sep 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of eltrombopag in Graft failure, sponsored by CHU de Lille. Started Sep 2019; status: terminated.
02
Drugs
eltrombopag
03
Conditions
Graft failure
Beyond the preview
Go deeper on NCT03948529.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03948529.